TerrAscend (TSNDF) Non Operating Investment Income (2021 - 2025)
TerrAscend's (TSNDF) quarterly Non Operating Investment Income came in at -$629000.0 in Q4 2025, down 2416.0% year-on-year from $27158.9 in Q4 2024, and down 62800.0% on a QoQ basis from -$1000.0 in Q3 2025.
TerrAscend (TSNDF) Non Operating Investment Income (2021 - 2025) Analysis & Trends
TerrAscend (TSNDF) has 5 years of Non Operating Investment Income data on file, last reported at -$629000.0 in Q4 2025.
- On a quarterly basis, Non Operating Investment Income fell 2416.0% year-over-year to -$629000.0 in Q4 2025; TTM through Mar 2026 was -$623000.0, a 36.43% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 473.53% from the prior year.
- Non Operating Investment Income for Q4 2025 stood at -$629000.0, down from -$1000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for TSNDF reached as high as $6.0 million in Q2 2021 and fell as low as -$1.7 million in Q2 2023.
- Historically, Non Operating Investment Income has averaged $126750.0 across 5 years, with a median of -$15000.0 in 2023.
- Across the five-year window, Non Operating Investment Income soared 380.0% in 2024 and sank 2416.0% in 2025, its largest moves.
- Year by year, Non Operating Investment Income stood at $6.0 million in 2021, then plunged by 99.23% to $46000.0 in 2022, then slumped by 619.57% to -$239000.0 in 2023, then soared by 89.54% to -$25000.0 in 2024, then sank by 2416.0% to -$629000.0 in 2025.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$629000.0 in Q4 2025, -$1000.0 in Q3 2025, and $7000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | TerrAscend | 164.05 Mn | 163.57 Mn | 34.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -629,000.00 |
| Dec 31, 2025 | -629,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | -742,000.00 |
| Mar 31, 2025 | -742,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | -227,000.00 |
| Jun 30, 2024 | -227,000.00 |
| Dec 31, 2023 | -239,000.00 |
| Dec 31, 2023 | -239,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | -1.66 Mn |